57.1 F
Los Angeles
Monday, May 23, 2022

Drugs

FDA Approves Biosimilar, Amgen’s Rival

NantWorks Strikes Deal with Sorrento Therapeutics

Report: Amgen May Bid Less for Onyx

Herbalife’s Earnings Up But Guidance Down

FDA Delays Afrezza Decision

Amgen Initiates Partial Drug Recall

Herbalife Soars on Higher Earnings, Revenue

Abraxis CEO Leaves

Amgen’s Profit Edges Up

FDA Delays Decision on MannKind Drug

Amgen Resolves Roche Patent Dispute

Billionaire Could Give King Hospital Shot in Arm

Latest Articles